Other

Osaka University

Otsuka Pharmaceutical Factory, Inc.

Hirotsu Bio Science Inc.

Ijunkai

Yamamoto, Hirofumi

Mori, Masaki

Yuichiro Doki

Masaki Mori

Hirofumi Yamamoto

Masahiro Tanemura

Xin Wu

Toshinori Ito

Yoshiaki Omura

Yoshiki Sawa

Hiroyuki Nakanishi

Susumu Miyazaki

Toshihiro Akaike

Kenichi Nagai

Shogo Kobayashi

Takaaki Hirotsu

Yuji Ueda

Hideshi Ishii

Norikatsu Miyoshi

Junichi Nishimura

Naotsugu Haraguchi

Satoru Kaifuchi

Toshimi Sugimoto

Masamitsu Konno

Hidetoshi Eguchi

Yasuhiro Miyazaki

Akira Myoui

Hiromitsu Hoshino

Shuji Takiguchi

Hiroaki Nagano

Akihiro Takata

Mori Masaki

A method of examining for cancer in a non-primate mammal such as a pet animal may include, for example, a method of examining or diagnosing for cancer in a non-primate mammal, including evaluating taxic behavior of nematodes toward a urine sample from a subject mammal.

Method for examining cancer in pet animal

The purpose of the present invention is to provide a colorectal cancer drug that uses microRNA exhibiting outstanding effectiveness in colorectal cancer patients, particularly colorectal cancer patients having a mutated KRAS gene. miR4689 and/or miR4685-3p can suppress the growth of colorectal cancer cells, particularly colorectal cancer cells having a mutated KRAS gene, and thus exhibit an effective antitumor effect.

Colorectal cancer drug, and method for predicting prognosis of colorectal cancer patient

Provided is a novel useful microRNA having improved anti-tumor activity, obtained by introducing a variation in a microRNA which is present in-vivo and which exhibits an anti-tumor effect. This microRNA containing a base sequence (SEQ ID NO: 1) obtained by varying a predetermined region of the base sequence of miR-29b is able to exhibit a particularly outstanding anti-tumor effect.

RNA sequence having anti-tumour activity

The present invention relates to methods for preventing or reducing the incidence of postoperative pulmonary complications in surgical patients after an esophagectomy. The inventors discovered that the occurrence of postoperative pulmonary complications after an esophagectomy may be reduced through the perioperative administration of ghrelin to surgical patients.

Method for preventing or reducing postoperative pulmonary complications

An object of the present invention is to provide an agent that potentiates the antitumor effect of an anticancer agent by allowing efficient accumulation of the anticancer agent in tumor tissue. The administration of carbonate apatite with the anticancer agent allows efficient accumulation of the anticancer agent in the tumor tissue to dramatically potentiate the antitumor effect of the anticancer agent.

Enhancer of anti-tumor effect of anti-cancer agent

A principal object of the present invention is to provide a pharmaceutical composition that can produce a high antitumor effect by efficiently delivering a drug with antitumor activity to tumor tissues with the aid of carbonate apatite nanoparticles. The present invention provides a pharmaceutical composition including carbonate apatite nanoparticles with an average particle size of at most 50 nm containing a drug with antitumor activity and a pharmacologically acceptable solvent in which the carbonate apatite nanoparticles containing the drug are dispersed.

Pharmaceutical composition for treating cancer using carbonate apatite nanoparticles

An object of the present invention is to provide a pancreatic islet transplantation technique that enables increase of graft survival rate of pancreatic islets after pancreatic islet transplantation, to maintain survival of pancreatic islets, and to reduce the number of transplanted pancreatic islets required for normalizing blood glucose level. When performing pancreatic islet transplantation, by transplanting pancreatic islets and adipose tissue-derived stem cells together, it is possible to significantly improve graft survival rate of transplanted pancreatic islets, and reduce by half the number of transplanted pancreatic islets required for normalizing blood glucose level.

Combined islet transplantation using pancreatic islets and adipose tissue derived stem cells

A major object of the present invention is to provide a method for producing induced pluripotent stem cells with low tumorigenesis potential and high induction efficiency. The invention provides a method for producing induced pluripotent stem cells comprising the step of introducing one or more nucleic acids that facilitate expression of at least one gene selected from the group consisting of NANOG, SOX2, OCT3/4, KLF4, LIN28, and c-MYC into somatic cells.

Method for producing induced pluripotent stem cells

The disclosed islet isolation method comprises: an injection step of injecting a preservation solution into the pancreatic duct of an excised pancreas; a preservation step of immersing the pancreas into an immersion fluid for preservation; a digestion step of breaking down the pancreas to provide pancreatic tissue; and a purification step of immersing the pancreatic tissue in a purification solution to provide islets. The digestion step consists of: an enzyme injection step of injecting an enzyme solution containing a digestion enzyme into the pancreas; a digestion initiation step of activating the digestion enzyme; a digestion termination step of inactivating the digestion enzyme; and a collection step of collecting the broken-down pancreatic tissue. The islet isolation method is characterized in that, by adding a neutrophil elastase inhibitor to the system before the digestion initiation step, the neutrophil elastase inhibitor is present inside the pancreas at the time point of starting the digestion initiation step. By using the above method and a protective solution which can be used in the method, islets having a size and shape suitable for transplantation can be obtained in high yields.

Pancreatic islet separation method, and protective solution for protecting pancreatic islet tissue

Growing community of inventors

Suita, Japan

Yuichiro Doki